Drug Trial Radar · NCT06692764
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
202
Actual
Start
Oct 30, 2024
Primary completion
Apr 18, 2025
Study completion May 2, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Fortrea
- First posted
- Nov 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory blood pressure monitoring (ABPM) in participants with ASCVD or risk equivalents and LDL-C ≥ 70 mg/dL, on stable medication.
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
PlaceboDrug
0 mg (Placebo). Participants will receive three bottles, each containing 35 tablets with placebo tablets. Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the placebo dose.
AZD0780Drug
Dose 1 Participants will receive three bottles, each containing 35 tablets: * 1 bottle of dose a AZD0780 tablets * 1 bottle of dose b AZD0780 tablets * 1 bottle of dose c AZD0780 tablets Participants will take 1 tablet from each bottle on each scheduled day of study intervention, which will provide the AZD0780 dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the effect of treatment with AZD0780 dose 1 versus placebo on ambulatory 24-hour average SBP at Week 4Time frame: Week 4
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Inglewood, California
Research Site
Northridge, California
Research Site
Pomona, California
Research Site
Boca Raton, Florida
Research Site
Hialeah, Florida
Research Site
Jacksonville, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Miami, Florida
Research Site
Ocala, Florida
Research Site
Port Orange, Florida
Research Site
Tamarac, Florida
Research Site
Chicago, Illinois
Research Site
Potomac, Maryland
Research Site
New Bedford, Massachusetts
Research Site
New Windsor, New York
Research Site
Beavercreek, Ohio
Research Site
Horsham, Pennsylvania
Research Site
Spartanburg, South Carolina
Research Site
Austin, Texas
Research Site
Dallas, Texas
Research Site
El Paso, Texas
Research Site
Hurst, Texas
Research Site
Mesquite, Texas
Research Site
Paris, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.